Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT06603818
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06342037
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06331598
- Locations
- 🇪🇸
Hospital Universitario Virgen; Servicio de Oncologia, Sevilla, Spain
🇪🇸Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT06328036
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT06267001
- Locations
- 🇨🇳
Ningbo No.2 Hospital, Ningbo, China
🇮🇹Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇮🇹Azienda U.S.L. 21 - Presidio Ospedaliero S. Spirito; U.O. Di Oncologia Clinica, Casale Monferrato, Piemonte, Italy
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Omico
- Target Recruit Count
- 96
- Registration Number
- NCT06003621
- Locations
- 🇦🇺
Border Medical Oncology Research Unit, Albury, New South Wales, Australia
🇦🇺Ramsay Health Care Australia Pty Ltd trading as The Border Cancer Hospital, Albury, New South Wales, Australia
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT05908786
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇺🇸University of Southern California (USC); Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 650
- Registration Number
- NCT05904886
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸UCLA MEDICAL CENTER; Alhambra, Alhambra, California, United States
🇺🇸UCSF Fresno at Community Cancer Institute, Clovis, California, United States
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05862285
- Locations
- 🇨🇷
Clinica CIMCA, San José, Costa Rica
🇨🇳Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan
🇲🇽Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-04-05
- Target Recruit Count
- 35
- Registration Number
- NCT05825625
- Locations
- 🇩🇪
Thoraxklinik Heidelberg, Heidelberg, Germany
🇩🇪Universitätsklinikum Essen (AöR)-Westdeutsches Tumorzentrum Essen, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.